Immunomedics
Gilead scoops up Immunomedics in deal worth $21 billion
September 14, 2020Sales and Marketing Gilead, Immunomedics, acquisition, pharma
The Board of Directors from both companies have unanimously agreed for Gilead to acquire Immunomedics for $88 per share in …
FDA approves Immunomedics’ Trodelvy for metastatic triple-negative breast cancer one month ahead of schedule
April 23, 2020Sales and Marketing Cancer, Immunomedics, Trodelvy, breast cancer, pharma
Immunomedics has scored approval with the FDA for Trodelvy (sacituzumab govitecan-hziy) in the treatment of metastatic triple-negative breast cancer, it …
Immunomedics’ whirlwind in the C-suite continues
April 10, 2018Manufacturing and Production, Medical Communications AstraZeneca, Immunomedics, Seattle Genetics, biotech, drugs, pharma, pharmaceutical
Immunomedics hasn’t had the most straight forward year, its $2 billion deal with Seattle Genetics was scuppered by activist investors, …
Board battle scuppers Seattle Genetics’ $2 billion licensing deal
May 8, 2017Sales and Marketing Immunomedics, Seattle Genetics, venBio
In another example of the influence that activist investors can have on the direction of a business, the potentially $2 …
Seattle Genetics’ prospective $2 billion licensing deal not without controversy
February 13, 2017Sales and Marketing Immunomedics, Seattle Genetics, enVio
Immunomedics announced on 10 February that it had entered a licensing agreement with Seattle Genetics for its leading experimental cancer …
Immunomedics’ chief financial officer resigns, shares fall
June 22, 2016Research and Development, Sales and Marketing Immunomedics, Shares, cfo, stock market
Shares in Immunomedics (Nasdaq: IMMU) fell as much as 11% after the company said its chief financial officer Peter Pfreundschuh …
